Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Primary Purpose : Treatment
Allocation : Randomized
Interventional Model : Parallel Assignment
Masking : Triple (Participant, Care Provider, Investigator)
Primary outcome measures:
Radiographic Progression-free Survival (rPFS), Overall Survival (OS)
The final analysis of TITAN confirmed that, despite crossover, apalutamide plus ADT improved OS, delayed castration resistance, maintained health-related quality of life, and had a consistent safety profile in a broad population of patients with mCSPC
Chi et al. 2021 JCO 39: 2294–2303)
The authors' conclusion was: In this trial involving patients with metastatic, castration-sensitive prostate cancer, overall survival and radiographic progression-free survival was significantly longer with the addition of [apalu…